The status of pathogen-reduced plasma

Transfusion and Apheresis Science

Volumn 43, Issue 3, 2010, Pages 393-399

  Sandler, S Gerald ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; BLOOD DERIVATIVE; ETHER; FRESH FROZEN PLASMA; METHOXSALEN; METHYLENE BLUE; OCTAPLAS; OCTAPLASLG; PLASMA SUBSTITUTE; POLYSORBATE 80; PSORALEN; RIBOFLAVIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; APHERESIS; ARTICLE; BLOOD; BLOOD DONOR; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; NONHUMAN; PLASMA TRANSFUSION; ULTRAVIOLET RADIATION;

BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; DISEASE TRANSMISSION, INFECTIOUS; DISINFECTION; HUMANS; PLASMA;

EID: 78649495559     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2010.09.006     Document Type: Article

References (71)

1. McCullough J. Pathogen inactivation/A new paradigm for preventing transfusion-transmitted infections. Am J Clin Pathol 2007, 128:945-955.
2. Allain J.P., Bianco C., Blajchman M.A., Brecher M.E., Busch M., Leiby, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005, 19:110-126.
3. Bryant B.J., Klein H.J. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 2007, 131:719-733.
4. Solheim B.G. Pathogen reduction of blood components. Transfus Apher Sci 2008, 39:75-82.
5. Prowse C. Properties of pathogen-inactivated plasma components. Transfus Med Rev 2009, 23:124-133.
6. Webert K., Cserti C.M., Hannon J., Lin Y., Pavenski K., Pendergrast J.M., et al. Proceedings of a consensus conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008, 22:1-34.
7. Seghatchian J., de Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006, 35:189-196.
8. Blajchman M.A. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Clin Biol 2009, 16:70-74.
9. Allain J.P. 10years of pathogen reduction/inactivation (PR/PI). Transfus Today 2009, 6:5.
10. Prince A.M., Horowitz B., Brotman B., Huima T., Richardson L., van den Ende M.C. Inactivation of hepatitis B and Hutchinson strain of non-A, non-B virus by exposing to Tween 80 and ether. Vox Sang 1984, 46:36-43.
11. Horowitz B., Wiebe M.E., Lippin A., Stryker M.H. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri-n-(butyl) phosphate detergent combinations. Transfusion 1985, 25:516-522.
12. Klein H., Dodd R.Y., Dzik W.H., et al. Current status of solvent/detergent-treated frozen plasma. Transfusion 1998, 38:102-107.
13. Anonymous ARC and VITEX finalize distribution agreement for solvent/detergent-treated plasma. AABB Wkly Rep 1998, 4(1):1-2.
14. Sandler S.G. It is time to bring back solvent-detergent plasma. Curr Opin Hematol 2007, 14:640-641.
15. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy and safety. Curr Opin Hematol 2004, 11:346-350.
16. Hellstern P. Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma?. Transfus Apher Sci 2008, 39:69-74.
17. Scully M., Longair I., Flynn M., Berryman J., Machin S.J. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007, 93(2):152-158.
18. Magner J.J., Crowley K.J., Boylan J.F. Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas). J Cardiothorac Vasc Anesth 2007, 21(3):410-413.
19. Inbal A., Epstein O., Blickstein D., et al. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis 1993, 4(4):599-604.
20. Flesland O., Seghatchain J., Solheim B.G. The Norwegian plasma fractionation project - a 12 year clinical and economic success story. Transfus Apher Sci 2003, 28:93-100.
21. Krusius T. Optimizing the use of plasma in Finland moving to Octaplas. In: Symposium: plasma safety: meet the expert, Cairo, Egypt, March 23, 2009.
22. Houston F., McCutcheon S., Goldmann W., Chong A., Foster J., Sisó S., et al. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008, 112(12):4739-4745.
23. Llewelyn C.A., Hewitt P.A., Knoght R.S.J., et al. Possible transmission of variant Creutzfeldt-Joacob disease by blood transfusion. Lancet 2004, 363:417-421.
24. Knight R. Prions, prion disease and blood. In: Symposium: plasma safety: meet the expert, Cairo, Egypt, March 23, 2009.
25. De Silvestro G., Bagatella P., Tison T., Quaino V., Carraro P., Tenderini M.L., et al. Virus-inactivated plasma - PlasmaSafe: a one-year experience. Blood Tranfus 2007, 5(3):134-142.
26. Lin L., Wiesehahn G.P., Morel P.A., Corash L. Use of 8-methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates. Blood 1989, 74:517-525.
27. Corash L. Virus-safe products: pathogen reduction and inactivation. Blood banking and transfusion medicine 2007, 3383-3396. Churchill Livingstone, Philadelphia. 2nd ed. C.D. Hillyer, L.E. Silberstein, P.M. Ness, K.C. Anderson, J.D. Roback (Eds.).
28. de Alarcon P., Benjamin R., Dugdale M., Kessler C., Shopnick R., Smith P., et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005, 45:1362-1372.
29. Hambleton J., Wages D., Radu-Radulescu L., Adams M., MacKenzie M., Shafer S., et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002, 42:1302-1307.
30. Ciaravino V., McCullough T., Cimino G., Sullivan T. Preclinical profile of plasma prepared using the Intercept blood system. Vox Sang 2003, 85:171-182.
31. Singh Y., Sawyer L.S., Pinkowski L.S., Dupuis K.W., Hsu J.C., Lin L., et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006, 46:1168-1177.
32. Mintz P.D., Bass N.M., Petz L.D., Steadman R., Streiff M., McCullough J., et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006, 107:3753-3760.
33. Schlenke P., Hervig T., Hervé I., Wiesel M.-L., Kientz D., Pinkoski L., et al. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 2008, 48(4):697-705.
34. Cazenave J.P., Waller C., Kientz D., Mendel I., Lin L., Jacquet M., et al. An active hemovigilance program characterizing the safety profiler of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010, 50:1210-1219.
35. Kientz D, Cinqualbre J, Hanau D, Isola H, Mendel I, Waller C, et al. Intercept plasma and liver transplantation. In: Fifth international intercept meeting, April 28-30, Rome, Italy.
36. Ruane P.H., Edrich R., Gampp D., Keil S.D., Leonard R.L., Goodrich R.P. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004, 44:877-885.
37. Rentas F., Harman R., Gomez C., Salata J., Childs J., Silva T., et al. Inactivation of Orientia tsutsugamushi in red blood cells, plasma and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 2007, 47:240-247.
38. Cardo L.J., Rentas F.J., Ketchum L., Salata J., Harman R., Melvin W., et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006, 90:85-91.
39. Cardo L.J., Salata J., Mendez J., Goodrich R. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavina and ultravioleta Light. Transfus Apher Sci 2007, 37:131-137.
40. Tonnetti L., Proctor M.C., Reddy H.L., Goodrich R.P., Lieby D.A. Evaluation of the Mirasol pathogen reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010, 50:1019-1027.
41. Larrea L., Calabuig M., Roldán V., Rivera J., Tsai H.-M., Vicente V., et al. The influence of riboflavin photochemistry on plasma coagulation factors. Transfus Apher Sci 2009, 41:199-204.
42. Buytaet-Hoefen K.A., Hendrix B.K., Gampp D., et al. Mirasol pathogen-reduced FFP Smith J, Rock G. Protein quality in Mirasol pathogen reduction technology-treated apheresis-derived fresh-frozen plasma. Transfusion 2010, 50:926-931.
43. Hornsey V.S., Drummond O., Morrison A., McMillan L., MacGregor I.R., Prowse C.V. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009, 49:2167-2172.
44. Mirasol PRT-treated fresh frozen plasma meets the Council of Europe Guidelines for untreated protein quality. (Council of Europe, European Directorate for the Quality of Medicine and Healthcare of the Council of Europe. Guide to the Preparation, Use & Quality Assurance of Blood Components. 14th ed. Strasbourg, 2008. ISBN 978-92-871-6330-1).
45. Smith J., Rock G. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion 2010, 50:926-931.
46. Bihm D.J., Ettinger A., Buytaert-Hoefen K.A., Hendrix B.K., Maldonado-Cordina G., Rock G., et al. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30[degrees]C/Blood component-collection and production. Vox Sang 2010, 98(2):115-118.
47. Zempleni J., Galloway J.R., McCormick D.B. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr 1996, 63:54-66.
48. Unna K., Greslin J.G. Studies on the toxicity and pharmacology of riboflavin. J Pharmacol 1942, 76:75-80.
49. Kumar V., Lockerbie O., Kiel S.D., Ruane P., Platz M., Martic C. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004, 80:15-21.
50. Goodrich R.P., Edrich R.A., Li J., Seghatchian J. The Mirasol PRT. System for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006, 35:5-17.
51. Clifton C.E. Photodynamic action of certain dyes on the inactivation of staphylococcus bacteriophage. Proc Soc Exp Biol Med 1931, 28:745-746.
52. Perdrau J.R., Todd C. The photodynamic action of methylene blue on certain viruses. Proc R Soc Lond (Biol) 1933, 112:288-298.
53. Wagner S.J. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 2002, 16:61-66.
54. Lambrecht B., Mohr H., Knüver-Hopf J., Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991, 60(4):207-213.
55. Seghatchian J., Walker W.H., Reichenberg S. Updates on pathogen inactivation of plasma using Theraflex methylene blue system. Transfus Apher Sci 2008, 38:271-280.
56. Mohr H., Knuver-Hopf J., Gravemann U., Redecker-Klein A., Mueller T.H. West Nile virus in plasma is highly sensitive to methylene blue-light treatment. Transfusion 2004, 44:886-890.
57. Huang Q., Fu W.-L., Chen B., Huang J.-F., Zhang H., Xue Q. Inactivation of dengue virus by methylene blue/narrow bandwidth system. J Photochem Photobiol B (Biol) 2004, 77:39-43.
58. Girones N., Bueno J.L., Carrion J., Fresno M., Castro E. The efficacy of photochemically treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma. Vox Sang 2006, 91:285-291.
59. Depasse F., Sensebe L., Seghatchian J., Andreu G., Samama M.M. The influence of methylene blue light treatment and methylene blue filter on fibrinogen activity states and fibrin polimerisation indices. Transfus Apher Sci 2005, 33:63-69.
60. Williamson L.M., Cardigan R., Prowse C.V. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?. Transfusion 2003, 43:1322-1329.
61. Cardigan R., Philpot K., Crookson P., Luddington R. Thrombin generation and clot formation in methylene blue treated plasma and cryoprecipitate. Transfusion 2009, 49:696-703.
62. Gravemann U., Kusch M., Koenig H., Mohr H., Mueller T.H. Thrombin generation capacity of methylene blue-treated plasma prepared by the Theraflex MB plasma system. Transfus Med Hemother 2009, 36:122-127.
63. Moog R., Reichenberg S., Hoburg A., Müller N. Quality of methylene blue-treated fresh-frozen plasma stored up to 27months 9letter. Transfusion 2010, 50:516-518.
64. FDA Liasion Meeting - 10/29/08. Accessed on May 22, 2010 at >Meetings & Events>Government/Advisory Meetings>FDA Liasion Meetings>Blood and Blood Components. http://www.aabb.org.
65. FDA Liasion Meeting 1/7/2010. Accessed on May 22, 2010 at >Meetings & Events>Government/Advisory Meetings>FDA Liasion Meetings>Blood and Blood Components. http://www.aabb.org.
66. Webert K.E., Cserti Christine M., Hannon J., Lin Y., Pavenski K., Pendergrast J.M., et al. Proceedings of a consensus conference. pathogen inactivation - making decisions about new technologies. Transfus Med Rev 2008, 22:1-34.
67. AuBuchon J.P. Current status of pathogen inactivation methods. Vox Sang 2010, 5:125-133.
68. Riedler G.F., Haycox A.R., Duggan A.K., Dakin H.A. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003, 85:88-95.
69. Eder A.F., Benjamin R.J. TRALI risk reduction: donor and component management strategies. J Clin Apher 2009, 24:122-129.
70. Eder AF, Herron Jr RM, Strupp A, Dy B, White J, Notari EP, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion, in press.
71. Sandler S.G. The case for pathogen inactivation of blood components. Curr Opin Hematol 2005, 12:471-472.